<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519555</url>
  </required_header>
  <id_info>
    <org_study_id>16-5010-16</org_study_id>
    <nct_id>NCT03519555</nct_id>
  </id_info>
  <brief_title>BIOSURE™ RG Knee Safety &amp; Performance Study</brief_title>
  <official_title>Safety and Performance of the BIOSURE™ REGENESORB Interference Screw in Knee Ligament Repair and Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Performance of the BIOSURE™ REGENESORB Interference Screw in Knee Ligament Repair&#xD;
      and Reconstruction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This post-market clinical follow-up (PMCF) study will prospectively evaluate the short-term&#xD;
      (6- and 12-month) safety and performance of the BIOSURE REGENESORB Interference Screw when&#xD;
      used for any of the following:&#xD;
&#xD;
      Knee repair:&#xD;
&#xD;
        -  ACL repair Posterior cruciate ligament (PCL) repair&#xD;
&#xD;
        -  Extra-capsular repairs&#xD;
&#xD;
        -  Medial collateral ligament (MCL)&#xD;
&#xD;
        -  Lateral collateral ligament (LCL)&#xD;
&#xD;
        -  Posterior oblique ligament (POL)&#xD;
&#xD;
        -  Patellar realignment and tendon repairs&#xD;
&#xD;
        -  Vastus medialis obliquus advancement&#xD;
&#xD;
        -  Iliotibial band tenodesis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2017</start_date>
  <completion_date type="Actual">October 5, 2020</completion_date>
  <primary_completion_date type="Actual">October 5, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Graft fixation survival</measure>
    <time_frame>6 months</time_frame>
    <description>Survival rate at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft fixation survival</measure>
    <time_frame>12 months</time_frame>
    <description>Survival rate at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival at 6 and 12 months</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>where failure is defined as graft repair failure for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - International Knee Documentation Committee Score</measure>
    <time_frame>Pre-Op, 6 months and 12 months</time_frame>
    <description>Patient Reported Outcomes using International Knee Documentation Committee Score. Scores summed and normalized to 100, minimum score is 0 points and maximum score is 100 points. The lower the score, the greater the disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Tegner Activity Scale</measure>
    <time_frame>Pre-Op, 6 months and 12 months</time_frame>
    <description>Patient Reported Outcomes using Tegner Activity Scale, subject indicates highest level of activity before injury and highest level of activity after injury. Levels on a scale from 0 to 10, with 10 being highest level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Lysholm Score</measure>
    <time_frame>Pre-Op, 6 months and 12 months</time_frame>
    <description>Patient Reported Outcomes using Lysholm Score, subject will answer eight questions on how knee pain has affected everyday life. Each question will be answered by placing a checkmark that best describes current condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EQ-5D-5L</measure>
    <time_frame>Pre-Op, 6 months and 12 months</time_frame>
    <description>Patient Reported Outcomes using EuroQol Five Dimensions Questionnaire, subject will check box describing health on mobility, self-care, usual daily activities, pain/discomfort, and anxiety/depression. There are five checkbox options for each: no problems, slight, severe, unable to do activity. Subject will indicate from a scale of 1 to 100 (100 best), how good or bad is current health.</description>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>ACL Repair</condition>
  <condition>Posterior Cruciate Ligament (PCL) Repair</condition>
  <condition>Medial Collateral Ligament (MCL)</condition>
  <condition>Lateral Collateral Ligament (LCL)</condition>
  <condition>Posterior Oblique Ligament (POL)</condition>
  <condition>Patellar Realignment and Tendon Repairs</condition>
  <condition>Vastus Medialis Obliquus Advancement</condition>
  <condition>Iliotibial Band Tenodesis</condition>
  <condition>Extra-capsular Repairs</condition>
  <condition>Knee Repair</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who have received BIOSURE™ REGENESORB Interference Screw in Knee Ligament&#xD;
        Repair and Reconstruction. This population will be used for safety analysis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has provided informed consent for study participation.&#xD;
&#xD;
          2. Subject is eighteen (18) years of age or older at the time of enrollment in the study.&#xD;
&#xD;
          3. Subject requires one of the following knee procedures:&#xD;
&#xD;
               -  Anterior cruciate ligament (ACL) repair&#xD;
&#xD;
               -  Posterior cruciate ligament (PCL) repair&#xD;
&#xD;
               -  Extra-capsular repair - Medial collateral ligament (MCL), Lateral collateral&#xD;
                  ligament (LCL), Posterior oblique ligament (POL)&#xD;
&#xD;
               -  Patellar realignment and tendon repair Vastus medialis obliquus advancement&#xD;
                  Iliotibial band tenodesis&#xD;
&#xD;
          4. Subject is willing and able to comply with study visit schedule and to complete study&#xD;
             procedures and questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has Body Mass Index (BMI) &gt; 40.&#xD;
&#xD;
          2. Subject has had total knee arthroplasty (TKA) in the study knee.&#xD;
&#xD;
          3. Subject has conditions that may interfere with graft survival or outcome (e.g. Paget&#xD;
             disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to&#xD;
             severe renal insufficiency or neuromuscular disease).&#xD;
&#xD;
          4. Subject has a known allergy to the study device or any of its components.&#xD;
&#xD;
          5. Subject, in the opinion of the Investigator, has an emotional or neurological&#xD;
             condition that would pre-empt their willingness to participate in the study, including&#xD;
             mental illness, mental retardation, drug or alcohol abuse, subject is pregnant, or&#xD;
             plans to become pregnant during the study.&#xD;
&#xD;
          6. Subject is entered in another investigational drug, biologic, or device study, or has&#xD;
             been treated with an investigational product in the past 30 days.&#xD;
&#xD;
          7. Subject is known to be at risk for loss to follow-up or failure to return for&#xD;
             scheduled visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Mangin</last_name>
    <role>Study Chair</role>
    <affiliation>Smith &amp; Nephew, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OrthoIllinois</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoCarolina Research Institute, Inc.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kelsey-Seybold Clinic/ Kelsey Research Foundation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

